282 related articles for article (PubMed ID: 25517316)
1. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
[TBL] [Abstract][Full Text] [Related]
2. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
3. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
4. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.
Salhi I; Cambon-Roques S; Lamarre I; Laune D; Molina F; Pugnière M; Pourquier D; Gutowski M; Picard JY; Xavier F; Pèlegrin A; Navarro-Teulon I
Biochem J; 2004 May; 379(Pt 3):785-93. PubMed ID: 14750901
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
6. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
[TBL] [Abstract][Full Text] [Related]
7. Expression of Müllerian-Inhibiting Substance/Anti-Müllerian Hormone Type II Receptor in the Human Theca Cells.
Cheon KY; Chung YJ; Cho HH; Kim MR; Cha JH; Kang CS; Lee JY; Kim JH
J Clin Endocrinol Metab; 2018 Sep; 103(9):3376-3385. PubMed ID: 29947765
[TBL] [Abstract][Full Text] [Related]
8. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
11. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis.
Anttonen M; Färkkilä A; Tauriala H; Kauppinen M; Maclaughlin DT; Unkila-Kallio L; Bützow R; Heikinheimo M
Lab Invest; 2011 Nov; 91(11):1605-14. PubMed ID: 21808236
[TBL] [Abstract][Full Text] [Related]
12. [Mullerian inhibiting substance type II receptor as a potential target for antineoplastic therapy].
Rak AY; Trofimov AV; Ischenko AM
Biomed Khim; 2019 Apr; 65(3):202-213. PubMed ID: 31258143
[TBL] [Abstract][Full Text] [Related]
13. High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging.
Ortega C; Herbet A; Richard S; Kersual N; Costa N; Pèlegrin A; Ducancel F; Couraud JY; Navarro-Teulon I; Boquet D
J Immunol Methods; 2013 Jan; 387(1-2):11-20. PubMed ID: 22910001
[TBL] [Abstract][Full Text] [Related]
14. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Song JY; Jo HH; Kim MR; Lew YO; Ryu KS; Cha JH; Kang CS; Donahoe PK; MacLaughlin DT; Kim JH
Int J Oncol; 2012 Jun; 40(6):2013-21. PubMed ID: 22344630
[TBL] [Abstract][Full Text] [Related]
15. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W
Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267
[TBL] [Abstract][Full Text] [Related]
17. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II.
Sakalar C; Mazumder S; Johnson JM; Altuntas CZ; Jaini R; Aguilar R; Naga Prasad SV; Connolly DC; Tuohy VK
J Immunol Res; 2015; 2015():630287. PubMed ID: 26618181
[TBL] [Abstract][Full Text] [Related]
19. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice.
Dutertre M; Gouédard L; Xavier F; Long WQ; di Clemente N; Picard JY; Rey R
Endocrinology; 2001 Sep; 142(9):4040-6. PubMed ID: 11517183
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
